Render Target: STATIC
Render Timestamp: 2024-12-23T11:09:20.963Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-10-04 16:01:09.061
Product last modified at: 2024-12-17T19:00:11.147Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: PTMScan (with Pricing)
PDP - Template ID: *******57cbce3

PTMScan® HS Ubiquitin/SUMO Remnant Motif (K-ε-GG) Kit #59322

Additional Information

This product is intended for peptide enrichment and mass spectrometry analysis. To learn more about our Proteomics Kits and Services please answer a few questions for our Proteomics group.

Contact the CST Proteomics Group

    Product Information

    Product Usage Information

    Important for SUMO Remnant: Wild type alpha-lytic protease (WaLP) is a serine endopeptidase that cleaves at the carboxyl terminal side of amino acids alanine, serine, threonine, and valine. Please check that the predicted SUMO sequence of your model organism contains AGG, SGG, TGG or VGG at the c-terminus to ensure reactivity.

    Storage

    All components in this kit are stable for at least 12 months when stored at the recommended temperature. Do not aliquot the antibody.

    Protocol

    Product Description

    PTMScan® HS is an enhanced PTMScan® methodology with improved identification of post-translationally modified peptides. PTMScan® technology employs a proprietary methodology from Cell Signaling Technology (CST) for peptide enrichment by immunoprecipitation using a specific bead-conjugated antibody in conjunction with liquid chromatography tandem mass spectrometry (LC-MS/MS) for quantitative profiling of post-translational modification (PTM) sites in cellular proteins. PTMs that can be analyzed by PTMScan® technology include phosphorylation, ubiquitination, acetylation, and methylation, among others. The technology enables researchers to isolate, identify, and quantitate large numbers of post-translationally modified cellular peptides with a high degree of specificity and sensitivity (HS), providing a global overview of PTMs in cell and tissue samples without bias about where the modified sites occur. For more information on PTMScan® products and services, please visit Proteomics Resource Center.

    Background

    Ubiquitin is a conserved polypeptide unit that plays an important role in the ubiquitin-proteasome pathway. Ubiquitin can be covalently linked to many cellular proteins by the ubiquitination process, which targets proteins for degradation by the 26S proteasome. Three components are involved in the target protein-ubiquitin conjugation process. Ubiquitin is first activated by forming a thiolester complex with the activation component E1; the activated ubiquitin is subsequently transferred to the ubiquitin-carrier protein E2, then from E2 to ubiquitin ligase E3 for final delivery to the epsilon-NH2 of the target protein lysine residue (1-3). The ubiquitin-proteasome pathway has been implicated in a wide range of normal biological processes and in disease-related abnormalities. Several proteins such as IκB, p53, cdc25A, and Bcl-2 have been shown to be targets for the ubiquitin-proteasome process as part of regulation of cell cycle progression, differentiation, cell stress response, and apoptosis (4-7).

    Small ubiquitin-related modifier 1, 2, and 3 (SUMO-1, -2, and -3) are members of the ubiquitin-like protein family (8). The covalent attachment of the SUMO-1, -2, or -3 (SUMOylation) to target proteins is analogous to ubiquitination.

    Ubiquitin and the individual SUMO family members are all targeted to different proteins with diverse biological functions. Ubiquitin predominantly regulates degradation of its target (8). In contrast, SUMO-1 is conjugated to RanGAP, PML, p53, and IκB-α, regulates nuclear trafficking, forms subnuclear structures, and regulates transcriptional activity and protein stability (9-13). SUMO-2/-3 forms poly-(SUMO) chains, is conjugated to topoisomerase II and APP, regulates chromosomal segregation and cellular responses to environmental stress, and plays a role in the progression of Alzheimer's disease (14-17).
    1. Ciechanover, A. (1998) EMBO J 17, 7151-60.
    2. Hochstrasser, M. (2000) Nat Cell Biol 2, E153-7.
    3. Hochstrasser, M. (2000) Science 289, 563-4.
    4. Bernardi, R. et al. (2000) Oncogene 19, 2447-54.
    5. Aberle, H. et al. (1997) EMBO J 16, 3797-804.
    6. Salomoni, P. and Pandolfi, P.P. (2002) Nat Cell Biol 4, E152-3.
    7. Jesenberger, V. and Jentsch, S. (2002) Nat Rev Mol Cell Biol 3, 112-21.
    8. Schwartz, D.C. and Hochstrasser, M. (2003) Trends Biochem. Sci. 28, 321-8.
    9. Matunis, M.J. et al. (1996) J. Cell Biol. 135, 1457-70.
    10. Duprez, E. et al. (1999) J. Cell Sci. 112, 381-93.
    11. Gostissa, M. et al. (1999) EMBO J. 18, 6462-74.
    12. Rodriguez, M.S. et al. (1999) EMBO J. 18, 6455-61.
    13. Desterro, J.M. et al. (1998) Mol. Cell 2, 233-9.
    14. Tatham, M.H. et al. (2001) J. Biol. Chem. 276, 35368-74.
    15. Azuma, Y. et al. (2003) J. Cell Biol. 163, 477-87.
    16. Li, Y. et al. (2003) Proc. Natl. Acad. Sci. USA 100, 259-64.
    17. Saitoh, H. and Hinchey, J. (2000) J. Biol. Chem. 275, 6252-8.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.